2. Trade policy
The conflict between the U.S. and China has been a huge market mover over the last year. While there are signs that a phase-one deal could be coming soon, investors should still watch out for further trade talks, UBS says.
If Trump is reelected in 2020, he "could become more adversarial with China," UBS said.
On the flip side, it seems that a Democratic president would "be unlikely to adopt a more conciliatory approach," UBS said.
3. Technology regulation
Investors should be prepared for greater scrutiny of big tech, UBS said. This is a big deal as technology looms large in the S&P 500, making up 16% of market value.
If President Trump wins reelection, tech giants could face scrutiny from antitrust regulators in addition to the review underway by the Department of Justice, UBS said.
And, a Democratic president would also spell trouble for big tech. Warren has released a plan to break up the biggest tech companies, and Biden has supported further investigation. Discussions on the topic could "exacerbate volatility" at the U.S. tech giants, UBS said.
4. Environmental legislation
President Trump has loosened environmental regulations, but if a Democrat wins in 2020, they would "almost certainly retighten them," according to UBS.
That could put pressure on the carbon-based energy sector, UBS said. It could also boost companies connected to clean energy, clean air, carbon reduction, and energy efficiency, according to UBS.
5. Redistribution
If President Trump is reelected, UBS thinks he might push to make the personal tax cuts from his Tax Cuts and Jobs Act in 2017 permanent.
But under a Democratic president, income tax rates for the wealthy would likely increase, UBS said, as the federal minimum wage and Social Security payments would also probably rise.
To hedge against this, UBS recommends adding exposure to consumer spending instead of business spending in 2020.
6. Healthcare reform
Healthcare is a huge debate topic in the lead-up to the 2020 election. President Trump has weakened the Affordable Care Act, but a Democratic president would likely strengthen it.
If a Democrat wins, UBS thinks "a move toward greater provision of public healthcare is likely." In addition, there could be some form of restriction on how much drug companies can charge for medication. This would hurt the healthcare sector and pharmaceutical industry, UBS said.